1.77
4.84%
-0.09
After Hours:
1.77
Rallybio Corp stock is currently priced at $1.77, with a 24-hour trading volume of 204.53K.
It has seen a -4.84% decreased in the last 24 hours and a +0.57% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.89 pivot point. If it approaches the $1.71 support level, significant changes may occur.
Previous Close:
$1.86
Open:
$1.86
24h Volume:
204.53K
Market Cap:
$73.37M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.9069
EPS:
-1.9516
Net Cash Flow:
$-60.27M
1W Performance:
-3.28%
1M Performance:
+0.57%
6M Performance:
-11.06%
1Y Performance:
-68.62%
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203 859 3820
Address
234 Church Street, Suite 1020, New Haven
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-17-23 | Initiated | H.C. Wainwright | Buy |
Apr-10-23 | Initiated | Wedbush | Outperform |
Dec-09-22 | Initiated | JP Morgan | Overweight |
Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
Aug-23-21 | Initiated | Cowen | Outperform |
Aug-23-21 | Initiated | Evercore ISI | Outperform |
Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Co. (NASDAQ:RLYB) Receives $12.20 Consensus Target Price from Analysts - MarketBeat
MarketBeat
Rallybio (NASDAQ:RLYB) Downgraded by JPMorgan Chase & Co. to Neutral - Defense World
Defense World
Rallybio Co. (NASDAQ:RLYB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Defense World
Rallybio (NASDAQ:RLYB) Downgraded to Neutral at JPMorgan Chase & Co. - MarketBeat
MarketBeat
JPMorgan cuts Rallybio stock to Neutral on near-term catalyst lack - Investing.com
Investing.com
HC Wainwright Reaffirms “Buy” Rating for Rallybio (NASDAQ:RLYB) - Defense World
Defense World
Rallybio Corp Stock (RLYB) Financials Data
Rallybio Corp (RLYB) Net Income 2024
RLYB net income (TTM) was -$74.56 million for the quarter ending December 31, 2023, a -11.87% decrease year-over-year.
Rallybio Corp (RLYB) Cash Flow 2024
RLYB recorded a free cash flow (TTM) of -$60.27 million for the quarter ending December 31, 2023, a -5.10% decrease year-over-year.
Rallybio Corp (RLYB) Earnings per Share 2024
RLYB earnings per share (TTM) was -$1.8316 for the quarter ending December 31, 2023, a +13.39% growth year-over-year.
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.
Cap:
|
Volume (24h):